Substance / Medication

Sevelamer

Overview

Active Ingredient
sevelamer
RxNorm CUI
214824

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.
Georgopoulos Christos, Duni Anila, Stamellou Eleni et al. · Hemodial Int · 2025
PMID: 39422162Meta-AnalysisFull text (PMC)
Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis.
Di Rienzo Gianluca, Crafa Pellegrino, Delsante Marco et al. · Pathologica · 2024
PMID: 39377503Meta-AnalysisFull text (PMC)
Systematic review and meta-analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control.
Basutkar Roopa Satyanarayan, Varghese Resia, Mathew Nina Kallanthanath et al. · Nephrology (Carlton) · 2022
PMID: 34882904Meta-Analysis
Effect of Calcium-based Phosphate Binders Versus Sevelamer on Mortality of Patients with Hemodialysis: A Meta-analysis.
Zhang Poxuan, Sang Shengmei, Huang Jinlan et al. · Iran J Kidney Dis · 2022
PMID: 35962636Meta-Analysis
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel Leena, Bernard Lisa M, Elder Grahame J · Clin J Am Soc Nephrol · 2016
PMID: 26668024Meta-AnalysisFull text (PMC)
Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
Tonelli Marcello, Wiebe Natasha, Culleton Bruce et al. · Nephrol Dial Transplant · 2007
PMID: 17906326Meta-Analysis
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.
Manns Braden, Stevens Lesley, Miskulin Dana et al. · Kidney Int · 2004
PMID: 15327423Meta-Analysis
Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke Steven K, Dillon Maureen A, Hemken Douglas E et al. · Adv Ren Replace Ther · 2003
PMID: 12879374Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sevelamer (substance)
SNOMED CT
395871000
UMLS CUI
C0718050
RxNorm CUI
214824

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.